<SEC-DOCUMENT>0001104659-20-120248.txt : 20201102
<SEC-HEADER>0001104659-20-120248.hdr.sgml : 20201102
<ACCEPTANCE-DATETIME>20201102071621
ACCESSION NUMBER:		0001104659-20-120248
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201102
FILED AS OF DATE:		20201102
DATE AS OF CHANGE:		20201102

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		201278962

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tm2034712d1_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C.
20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16<BR>
OF THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the month
of November 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File
Number 001-39446</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CureVac N.V.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Friedrich-Miescher-Strasse 15, 72076</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>T&uuml;bingen, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>+49 7071 9883 0</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Address of principal executive offices)
</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 20-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FORM
40-F&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant
by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule
12g3-2(b) under the Securities Exchange Act of 1934:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">YES&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NO&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If &ldquo;Yes&rdquo; is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">On November 2, 2020,
CureVac N.V. (the &ldquo;Company&rdquo;) issued a press release reporting interim Phase 1 data for its COVID-19 vaccine candidate,
CVnCoV. The press release is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The information
in this Form 6-K (including Exhibit 99.1) shall not be deemed &ldquo;filed&rdquo; for purposes of Section 18 of the Securities
Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">CUREVAC N.V.</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 2%"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; white-space: nowrap; vertical-align: top; width: 28%"><FONT STYLE="font-size: 10pt">/s/&nbsp;Franz-Werner&nbsp;Haas,&nbsp;LLD,&nbsp;LLM</FONT></TD>
    <TD STYLE="vertical-align: top; width: 20%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt"><I>Chief Executive Officer</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: November 2, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">EXHIBIT INDEX</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 0.9in; text-align: center"><FONT STYLE="font-size: 10pt">EXHIBIT NO.</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 0.1in">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">DESCRIPTION</FONT></TD></TR>
<TR>
    <TD STYLE="padding-top: 3pt; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-top: 3pt; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-top: 3pt; vertical-align: top"><FONT STYLE="font-size: 10pt">CureVac N.V. Press Release dated November 2, 2020.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2034712d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>CureVac Reports Positive Interim
Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Balanced immune response with strong
induction of binding, and neutralizing antibodies and first indications of T cell activation</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.85pt"></TD><TD STYLE="width: 17.85pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 7.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Quality of immune response
                                                                                                                 comparable to recovered COVID-19 patients, closely mimicking immune response after natural COVID-19 infection</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>CVnCoV generally well tolerated across
tested dose range of 2-12&micro;g</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Data support 12&micro;g dose for
pivotal Phase 2b/3 clinical trial</I></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="padding-right: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>On track to initiate pivotal Phase
2b/3 before end of 2020</I></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>T&Uuml;BINGEN,
Germany/ BOSTON, USA &ndash; November 2, 2020</B> &ndash; CureVac N.V. (Nasdaq: CVAC), a clinical-stage biopharmaceutical
company developing a new class of transformative medicines based on messenger ribonucleic acid (&ldquo;mRNA&rdquo;), today
announced positive interim data from its ongoing Phase 1 dose-escalation study evaluating the safety, reactogenicity and
immunogenicity of CVnCoV, its investigational SARS-CoV-2 vaccine candidate. The vaccine candidate was generally well
tolerated across all tested doses (2-12&micro;g) and induced strong binding and neutralizing antibody responses in addition
to first indication of T cell activation. CureVac intends to provide a detailed Phase&nbsp;1 data overview and publication in
a scientific journal in the coming weeks. CVnCoV is currently also being investigated in a Phase 2a clinical trial in older
adults in Peru and Panama.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&quot;<I>We are very encouraged
by the interim Phase 1 data. It represents a critical milestone in our COVID-19 vaccine program and strongly supports the advancement
of our vaccine candidate</I>,&quot; said <B>Dr. Franz-Werner Haas, Chief Executive Officer of CureVac</B>. &quot;<I>Following further
data readouts and discussion with regulatory authorities, we remain fully committed and on track to initiate a pivotal Phase 2b/3
trial before the end of 2020.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">The Phase 1 study has enrolled
to date more than 250 healthy individuals aged 18 to 60 years. Individuals were vaccinated intramuscularly with CVnCoV at escalating
dose levels of 2, 4, 6, 8 and 12&micro;g on days 1 and 29. Per dose level, the trial included up to 10 participants who had previously
tested positive for a COVID-19 infection (seropositives) to further evaluate the safety and immunogenicity of CVnCoV in this sub-population.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">The data support the decision
to advance the 12&micro;g dose in the upcoming pivotal Phase 2b/3 study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">Immunogenicity data showed
induction of binding antibody titers, translating into titers of virus neutralizing antibodies
at all tested dose levels. Geometric Mean Titers (GMTs) of binding and neutralizing antibodies of study participants were compared
to peak serum titers of 67 symptomatic convalescent COVID-19 patients (human convalescent sera, or HCS). The applied HCS panel
was composed to provide a medically relevant comparator to validate CVnCoV potency. The panel was highly representative of the
immune activation of seriously ill patients with multiple symptoms of whom approximately 24% were hospitalized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">At 12&micro;g, GMTs of binding
antibodies increased to the level measured in the HCS panel. Virus neutralizing antibodies increased to HCS levels at 12&micro;g
and were measured in a live-virus micro-neutralization assay. Analysis of T cell mediated immunity is ongoing. Early data show
indications of functional T cells confirming activation of cellular immune response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&ldquo;<I>These initial data
show a robust and highly efficient immune response to our natural mRNA-based CVnCoV vaccine candidate, including antibody and initial
T cell responses at the level of a relevant panel of symptomatic convalescent patients,</I>&rdquo; said <B>Dr. Mariola Fotin-Mleczek,
Chief Technology Officer of CureVac</B>. &quot;<I>We are grateful to all study volunteers who are helping to enable the development
of a vaccine that will provide the best possible protection for people.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">CVnCoV&rsquo;s unique mode
of action mimics the natural immune response to the infection observed in recovered COVID-19 patients. This is reflected in the
relative proportion of neutralizing to binding antibody levels, which are similar in vaccinated individuals and convalescent patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;<I>The data are highly encouraging,</I>&rdquo; said <B>Prof.
Dr. Peter Kremsner, Director of the Institute of Tropical Medicine of the University of T&uuml;bingen and lead investigator of
the Phase 1 trial</B>. &ldquo;<I>In this accelerated development program, it is paramount to ensure safety while generating a favorable
level of immunogenicity. With this study, we had a strong focus on identifying the optimal dose for CVnCoV and we have succeeded
in that.</I>&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reactogenicity of CVnCoV was continuously monitored by a Data
and Safety Monitoring Board, and the vaccine was generally well tolerated across all tested doses. No related serious adverse events
were observed. At 12&micro;g, grade 3 adverse events occurred mostly after administration of the second dose and included fatigue,
headache, chills, muscle pain, and to a lesser extent, fever. All reported events were transient and resolved rapidly, usually
within 24 to 48 hours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Formulation of CVnCoV is based on state-of-the-art lipid nanoparticle
(LNP) technology licensed from CureVac&rsquo;s long-standing partner Acuitas Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>About CVnCoV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">CureVac began development
of its mRNA-based COVID-19 vaccine candidate in January 2020. The compound is an optimized, non-chemically modified mRNA, encoding
the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus. The Phase 1 clinical study of CVnCoV began in June
2020 at clinical study centers in Germany and Belgium in collaboration with the Coalition for Epidemic Preparedness Innovation
(CEPI). At the end of September 2020 CVnCoV entered a Phase 2a clinical trial in Peru and Panama, extending clinical studies into
older adults and regions with high-incidence of COVID-19 infections. CureVac plans to initiate a pivotal Phase 2b/3 clinical study
by the end of 2020. Clinical trial material is provided by the company&rsquo;s substantial production capacities for mRNA vaccines
at its headquarters in T&uuml;bingen. The company is currently expanding those manufacturing capacities to allow for broad-scale
manufacturing of CVnCoV for potential commercial supply preparedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;&nbsp;</B></P>

<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white"><B>About CureVac</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.35pt 0pt 0; background-color: white">CureVac is a global clinical-stage
biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing
and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the
use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting
a broad range of diseases. Based on its proprietary technology, the company has built a deep clinical pipeline across the areas
of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public
offering on the New York Nasdaq in August 2020. It is headquartered in T&uuml;bingen, Germany, and employs approximately 500 people
at its sites in T&uuml;bingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>CureVac Media Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">Thorsten Sch&uuml;ller, Vice
President Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">T: +49 7071 9883-1577</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">thorsten.schueller@curevac.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>CureVac Investor Relations
Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">Dr. Sarah Fakih, Vice President
Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">CureVac, T&uuml;bingen, Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">T: +49 7071 9883-1298</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">M: +49 160 90 496949</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">sarah.fakih@curevac.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"><B>Forward-Looking Statements<BR>
</B><FONT STYLE="background-color: white">This press release contains statements that constitute &ldquo;forward looking statements&rdquo;
as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express
the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac (the &ldquo;company&rdquo;) regarding
future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of the
company&rsquo;s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking
statements by terminology such as &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;plan,&rdquo; &ldquo;seek,&rdquo; &ldquo;project,&rdquo; or &ldquo;expect,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo;
 &ldquo;would,&rdquo; &ldquo;could,&rdquo; &ldquo;potential,&rdquo; &ldquo;intend,&rdquo; or &ldquo;should,&rdquo; the negative
of these terms or similar expressions. Forward-looking statements are based on management&rsquo;s current beliefs and assumptions
and on information currently available to the company. However, these forward-looking statements are not a guarantee of the company&rsquo;s
performance, and you should not place undue reliance on such statements.&nbsp; Forward-looking statements are subject to many risks,
uncertainties and other variable circumstances, including negative worldwide economic conditions and ongoing instability and volatility
in the worldwide financial markets, ability to obtain funding, ability to conduct current and future preclinical studies and clinical
trials, the timing, expense and uncertainty of regulatory approval, reliance on third parties and collaboration partners, ability
to commercialize products, ability to manufacture any products, possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition and consolidation in the company&rsquo;s industry, the effects
of the COVID-19 pandemic on the company&rsquo;s business and results of operations, ability to manage growth, reliance on key personnel,
reliance on intellectual property protection, ability to provide for patient safety, and fluctuations of operating results due
to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers
are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company&rsquo;s control and
could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included
in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation
to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events
or developments, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7.5pt 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further information, please reference the company&rsquo;s
reports and documents filed with the&nbsp;U.S. Securities and Exchange Commission&nbsp;(SEC). You may get these documents by visiting
EDGAR on the&nbsp;SEC&nbsp;website at&nbsp;www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="width: 50%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ *T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4ZS=<\2:
M5X9M/M6K:A;Z?!V>XD"9/H,]3["O$_C'^T5<:+K$GA?PA"+S6=_D2W07>(Y"
M<;(U_B8'CG(SQ@GI0\*_LTZEXJG76?B%K-U=7<P#&QCEW,.^UW.0/]U>G8U\
M[5S656K+#X"G[22W>T5ZOKZ(^MHY'"C0CB\TJ^RA+X4E><O1=%YLZ#Q)^UAX
M4TMGBTFVO-<E!P&C3RHB<XQN;YO_ !VK_P *_BIXN^('B9EO_##:+H(MV=9W
MBD):3*[0)#A2,$]!7=>&?AOX9\'1H-(T6TM'48$VS?+_ -]MEOUJMX+^(,/C
M+6O$NG1V4EJVBW7V5Y'<,)3N=<@#I]S]:5.GC56IO%XA*[TC&.CLKVN]=@JU
MLN>'JK X5OE6LYRU5W9/E5EOZG6T50U[55T+0]1U)XS,MG;27!C4X+!%+8!]
M\5R:?%:W?X5GQM_9\OD;"WV3S!NXF\K[V,=>>E>U4Q-*BW&<K-)R^2W9\]1P
M=>O%2IQNG)1_[>>R^9W=%>667Q>\1:C9P7=M\/-4EMYXUECD6X7#*PR"/E[@
MUI>#OBTOB/Q5-X<U+0K[P_JZP?:$ANL%9$SC(/'OVQP>>*YH9CAIRC%2?O;7
MC)7^;21V5,IQE.,IN*:CJ[2BVEZ)MGH-%><:Y\8C;>*K[P_HGAS4/$-]8JIN
MFMR$CCR,@;CGG\OTI@^)WBG(S\.=4 _Z^4_PH>8X9-Q3;MII&35UOJDT"RG%
MN*DXI72:O**=GL[-IZGI5%>1?%#]H)/A3J&DKJOAF^.F:C&LB7HD4%#QOC9,
M<.N1QG!R,'KCU33M0MM6T^VOK.9+FTN8UFAFC.5=&&0P]B#7KRI3C"-1K26Q
M\Y3Q5&K6GAX2]^&Z[?UW6AA_$;QW8?#;P?J.OZ@<Q6R?NX<X,TAX1![D_D,G
MM7S7\ ?A;??&/4M;^('C"YO!#J$K+:I;SO"9'!Y<%3D(@&Q1G'!'\-1_$G4K
MO]IKXT6?@S1YF'A71I"]U=1\J2IQ)+Z'^XG7KGHQKU;QW\;-!^"VN>'?"=E8
M>9I]ND8O_LZEAI]L<)&QQWW,I.><8[N#7M4Z=3#TE2I+][/5^2_S9\;7Q%#,
M,2\3BG;#47RJ^TIO1OS4?^#M<U6^ XM91)IGCKQAII'2(:H98?\ OAE/\Z!X
M)^)NCL[Z=\0K75H_X+;6-*0 ?62,AC^5>GPS1W,,<T+K+%(H=)$.592,@@]Q
MBO+_ !!\=#:>,]0\,>'_  OJ?B?4M.56O&M2L<418 @;CGGGT'?&<&N"G4KU
MFTDG;NE^;/>Q&'P.$BI2;A?1<LIZOR47K]PG_"8?$_P[L&L>"=/U^(?ZRY\/
MW^PJ/412C<WT!JQI?[0OA*XO$LM8:^\)ZBPS]EU^U:V/!P3N.5QGN35/_A;G
MC'_HEFK_ /@7'_\ $UWW]GVGC+PW:KKNBQ%+J!))M.OXTE\IF4$HW!&03C(]
M*<U"*_>P2_PO]+O]"*$ZM1M86LW;I.#M]]H/\S5M;J"^MX[BVFCN()!N26)@
MRL/4$<&I:\3UWX$:EX1EEU;X7ZW/H%X"9'T>XE,EE<GJ1AL[2?4Y'IMZUH?!
MWX\1>/M0N?#>O6/]@^,;(LL]B^0DNW[QCSSD=2ISQR"0#C.6'YH.I1?,EOW7
MJOU1TT\P<*T</BX<DY;.]XR]'IKY-)]KGKE%%%<1[)\/?#Z5?A?\=H!XLR&M
M[F2*6YF!P&9659>>HRP;/H<^E?;T4R3Q)+$ZR1N RNIR&!Y!![BN*^)GP?T'
MXH68748C!?QKB&^@ $B#T/\ >7V/J<$9KQJW\+_%GX'EAHTH\3Z"AW?9U4R@
M#_KGG>IZ_<./4FOB\+"OD+G3E3<Z+=U*.K7JOU_X9?HN-J8;BB-.K&JJ>(BN
M5QEI&7^%[+?9_I=_3M>,_!&XCC^('Q0B:15D.K%@C$ X\R;G'I67X?\ VM-'
M>3[-XDT>\T6Z4[9&C'FQJ?<'##Z8-;HT#X3_ !JU-KR(6NI:E(OF.(9I;>9@
M,#<R J3C@9(]*[I8RACJE*K@ZD92@W[K?*W=-=F^O8\RGE^)RRE7HX^E.,)I
M>]%*25I*7=*SM_,=S\1+J&+X?^)6>6-%_LVY&68 9,3 5Y##G_AD4^OD-_Z6
M&NT@_9M^'MO,L@T-V*G(#WLY'Y;Z[;4?".DZIX:;0)K-%TAHUB^RPDQJ%4@@
M#;C&"!TK6KA,5BI3G448WA*"LV]96U?NJVWF<]''8+!PI4Z3E)*I&;;BHZ1O
MHES2N]>Z/*_!T?Q=_P"$1T/[!+X1%C]A@\CSQ<>9Y?EKMW8XSC&<=ZJ^!6UF
M3X]7*^,C"WB"+2L6ATW_ (]?)W<]?FSEFZ_[7M7MNFZ?!I.GVMC:IY=M:Q+#
M$F2=J* %&3R> *SO^$/TK_A*O^$C^SG^V/L_V7S_ #&QY><XVYV_CC-4\MFO
M8N-1OE:;3=UIVTW["6<4Y>W4J48J<9).,4G=O2[OL^IX;I.AZWK?QL\?QZ+X
MI/AF17A:3%JDYF&#CAB,8]O6N^L? ?C>WO()9_B;)<P(X9X?[*A7>H/*YW<9
MK:\7?!WPAXXOC>ZOHZ3WAQNGBEDB9L# W%&&>.,GL*P?^&9_AY_T!9O_  .N
M/_BZY*>75Z+DE'FO)N_M)QW;?PI6Z_,[JF;87$1@W-Q:C&+7L:<_ABE\3:;O
M:_EL=-\3_AYIWQ2\&7NA7X $PWV]QC)@F .QQ^>#Z@D=Z^.['XR>+OA3X,\0
M?"VYM9SKJ7'V2RN$)9H$<GS%7N<@@H1_?)_NBON/1='M?#^E6NFV,9BL[6,1
M1(6+%5'09)R?QKFM:^%'A_7O'^C^,+NUW:MIL;)&1C;(?X&<=RG.T^I'H,?>
M8+%JE#V>(C=;V[27Z=#\CSC*JF*JJO@9\D_A;VO![]]5NM?GL>8>#=%T_P#9
M7^"T^J:C$D_B2^"M)$/O37# ^7;C'9>2<9_C(["N9\ OJ6E^'_$*^*?AOXHU
MW6_$CNVJ77V4 %"3M1,G*A0<CI@].%7'T+X@\ :'XJUO2-5U6T:\N]*?S+,/
M*_EQOD'=L!VDY"\D'H*Z*J^N*S;5Y2=V]O1*W3^NA"R>7-&$)\M.FK122>Z]
MYRNK7>WI?NSY^_9O\=:AH]U+\.O$MK>Z;>VJ-/HPU*/RY9K3)PA'3*X)&.P8
M#A*L?"::.+]HKXK(\BH[&V*JS $X') []?UKU?Q)X T/Q9JFDZGJ-HSZAI4G
MFV=U%*\3QG(.,J1D9 X.1^9K$\;? OP1\0M2.H:YH<=Q?D -<1320N^!@;BC
M#=QQD]@!3>(HSE-M-<ZUMT=T[K7K84<OQE&%*$9*?LI7C=M7CRM6=D[-7TWN
MDMCNO.C_ +Z_F*<#GD<BO(#^R?\ #!06.@S #G)U&Y_^.5JZM\8O 'PQTNTT
M>/5H[@V<26MOI^GL;J8!5"JAP3@X ^^17)[&-1VH7D_3_@L]58N=!.>.Y*<>
M_/?\XQ_4]+KX^\<2CQ=^V/H?_"*MYEQ8RVPU"X@&5S&V9BS#TCPASW7%>BZE
MK7Q2^,T;6>AZ8_P^\-S#$FI:B2+V1#_<0<K^&/9Z] ^%/P;T#X1Z;)#I<;3W
MUP!]IU"XP99CZ?[*_P"R/QR>:[:3C@E*4W>;35EK:_?_ "/&Q4:F=2ITZ47&
ME&2DY-6O;913U_[>=EVN=Y1117D'UH4444 8^O>#]#\41[-6TFSU#C :XA5F
M7Z-C(_ US_A7X,^%O!/B)]9T6SDLKEHFB:,3,\9#$$\-D]AWKN**Y9X6A4FJ
MLH)R6SMK]YVT\;B:=-T85)*#T:N[/Y;!11174<05!?7T&FV5Q=W,@BMX(VED
MD()VJHR3Q["IZQ?&?C#2OA_X7U'Q%KER;/2=/B\ZYG",^Q<@9VJ"3R1T% G>
MVAR/_#1GPZSA_$L<1_Z;6TZ?^A(*=_PT5\-C_P S=8?FW_Q-7OC9X^O_ (8_
M#'6O$FEZ6NMZI:B&.TTYG*"XFEF2*-"P!(RT@[5VK0QMUC4_4"NCFH?RO[U_
M\B<')C?^?D?_  !__)GG#_M(?#6/KXMLR?\ 961OY+49_:4^'1XBUZ2X/I!I
M]U)_*.O2UA1>B*/H*X+QE\9K#P?XD70AX;\6:[J!B69CHN@W%Q;HK$@!KC:(
M@>.F_(XSC-/FH?RO[U_\B+V>._Y^0_\  '_\F5&^/_AZ1-UEIOB'4_06FC3L
M3^:BHH_C3J&H9&G?#CQ=*>S7MFEJI_%GS^E;_A3XI:/XJUZ;0A#J&D:_%:_;
M6TK5K5K><V^_9YJYRKKN^4E2<'&<9%6O''Q'T'X<MX>_MZ[:RCUW5H=$LY?+
M9D-W,KF)'('RABFT$\;F4=Q3]I16T/O?^5B?88N7Q5[>D4OS<CE%\:?%#5&9
M;3X>6>DK_#-JFLQR9]RD8R/SJ,^'OB]KL>+WQ7H/AK<>?['T]KE@/3,Q'/O7
M7_$#XE>&?A;HHU;Q3J\.D6#/Y:R2*SEC@L<*@+$*H9F(&%569L*"1T5M<PWE
MO%<6\J3P2H)(Y8V#*ZD9# C@@CO1]8Y?A@E\K_G<7U%R_BUIR^?+_P"D*)Y6
M_P"SS9:XS-XK\4>(/%*N,/:W-X8K8_2-,8_ UVWA?X<^&/!8']BZ'9:?)C'G
M1Q RD>[G+'\371T5,\15J+EE+3MT^[8UHX#"T)<\*:YN[U?WN[_$**8DT<DD
MB)(K/&0'52"5)&0".W!!_&N-^(FH>(+?6? EIH=W'8V]]KRQ:I,\2R,;1+6Y
MF,:YX!=XHUW=0&;&#@CG.\[6BN3^(OBZX\+^'S)I@M9M5GN[:P@^U,?)ADGE
M6-'EVD':-V< @M@*",Y'S/)^VMK'@+PKI&L>(=%DUZ+69)H[>&.+[%<VS1+$
MSB13G*L)XRF54X#'YU*.0#[$HHHH **** "BBB@ KA/C!\/M7^)WAB3P_8>(
MT\.Z?>1S0Z@W]FQW<L\;1E55#(VU,,0Q.UB=N!MZUW=% 'STV@_$_7?#TFE7
M45])XRLY;&Z:^UJXMCX?O&M[R&9O*-NHFC\Q8VP&BW)G!SC)ZEO#7Q(\*^)]
M URVUAO&7]H7:VGB+2IIDL[.SMGZ7-DA5B#"1@HS%I5=B6W*N/7** /G_P"
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-W'"@X&3ZUU=% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
